查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2026812

甲溝炎治療市場預測至2034年—按產品、類型、最終用戶和地區分類的全球分析

Paronychia Treatment Market Forecasts to 2034 - Global Analysis By Product, Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球甲溝炎治療市場規模將達到 6.606 億美元，並在預測期內以 9.2% 的複合年成長率成長，到 2034 年將達到 13.358 億美元。

甲溝炎是一種常見的指甲感染疾病，會導致手指甲或腳趾甲周圍皮膚發炎。它可能由細菌、真菌或兩者共同引起，導致紅腫和疼痛。治療方法包括熱敷、適當引流、局部或口服抗生素治療細菌感染，以及抗真菌藥物治療真菌感染。在嚴重或復發的情況下，可能需要手術治療。

糖尿病患者數量顯著增加

由於免疫功能減弱、神經病變和血液循環不良，糖尿病患者更容易發生指甲感染疾病，例如甲溝炎。隨著全球糖尿病盛行率的上升，糖尿病相關併發症（包括指甲疾病）的發生率也隨之增加。糖尿病患者在控制感染疾病常常面臨挑戰，因此甲溝炎需要及時有效的治療。

假藥

假冒偽劣藥品構成嚴重威脅，可能為尋求緩解甲溝炎（指甲感染）的患者提供無效、劣質甚至有害的治療方法。這些未經許可的藥品缺乏品管、療效不足和安全標準，引發醫護人員和病人對治療可靠性和潛在副作用的擔憂。此類仿冒品的存在削弱了市場對正規產品的信心，阻礙了市場成長。

技術進步

創新技術正在提供改良的藥物配方、標靶給藥系統和先進的診斷工具。奈米技術、經皮貼片以及先進的影像和分子檢測技術使得更有效、更精準的治療方法成為可能。此外，遠端醫療實現了遠距會診，擴大了患者獲得專科護理的機會。這些技術進步提高了治療效果，改善了患者體驗，並提升了甲溝炎治療的整體水平，從而為市場創新和成長創造了機會。

意識水平低

對甲溝炎及其症狀缺乏了解，以及對及時就醫重要性的認知不足，會導致診斷和治療延誤。對預防措施和現有治療方法的認知不足，會阻礙早期療育，使指甲感染疾病進一步惡化。這種認知水平低下會影響市場成長，導致患者群體縮小，並阻礙有效甲溝炎治療方法的廣泛應用。

新型冠狀病毒（COVID-19）的影響

致命的冠狀病毒在全球迅速蔓延，導致醫院不堪重負，迫使醫療資源重新分配，並限制了非緊急醫療服務的取得。這嚴重擾亂了醫療系統，影響了甲溝炎的診斷、治療和管理，並延遲或減少了人們獲得醫療服務的機會。感染疾病及其帶來的疼痛和發炎等不良反應的患者，必須等待醫療服務恢復才能解決他們的問題。

在預測期內，慢性甲溝炎預計將佔最大佔有率。

慢性甲溝炎市場預計將佔據最大的市場佔有率。慢性甲溝炎是一種長期疾病，通常由真菌或細菌感染疾病、刺激物或反覆外傷、潛在疾病等誘發因素引起。慢性甲溝炎的治療方法包括局部使用抗真菌藥物、口服藥物、熱敷以及採取預防措施以應對潛在的刺激物。此外，由於慢性甲溝炎容易復發，因此需要長期且專業的治療。正因如此，市場對治療此類疾病的需求十分旺盛。

在預測期內，慶大霉素軟膏細分市場預計將呈現最高的複合年成長率。

預計在預測期內，慶大霉素軟膏市場將實現顯著成長。慶大霉素軟膏含有慶大霉素，這是一種對多種細菌有效的抗生素。直接塗抹於患甲後，慶大霉素軟膏可有效對抗細菌感染，減輕炎症，促進癒合。此外，其局部用藥特性和抗菌功效使其成為治療輕度至中度細菌性甲溝炎的有效選擇。此細分市場專為需要標靶抗菌治療的患者而設計，並豐富了市場上可用於治療細菌性甲溝炎等感染疾病的局部用藥選擇。

市佔率最大的地區：

在預測期內，亞太地區佔據了最大的市場佔有率，這主要得益於健康意識的提高、指甲感染疾病盛行率的上升以及醫療基礎設施的改善。該地區多元化的人口結構和不斷變化的生活方式也導致了甲溝炎的發病率增加。此外，甲溝炎患者人數的增加、治療支出的增加以及政府主導的旨在改善醫療基礎設施和意識提升對指甲感染疾病認知的各項舉措，都在推動市場成長需求。

預計複合年成長率最高的地區：

在北美，老年人口的快速成長、大眾對有效治療方法的認知度提高，以及美國和加拿大等國家主要市場參與者的強大影響力，預計將推動預測期內市場實現盈利成長。此外，包括新型局部療法、抗真菌藥物和抗生素在內的尖端甲溝炎治療方法的快速發展，正在增加診所和醫院提供的治療方法的多樣性，這可能對市場產生積極影響。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球甲溝炎治療市場：依產品分類

  • 莫匹羅星軟膏
  • 慶大霉素軟膏
  • 夫西地酸軟膏
  • 雙氯西林
  • 其他產品

第6章：全球甲溝炎治療市場：依類型分類

  • 慢性甲溝炎
  • 急性甲溝炎
  • 化膿性甲溝炎
  • 念珠菌性甲溝炎
  • 其他類型

第7章 全球甲溝炎治療市場：依最終用戶分類

  • 皮膚科診所
  • 醫院和診所
  • 其他最終用戶

第8章：全球甲溝炎治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Glenmark Generics Ltd
  • Eli Lilly Company
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Jonakayem Pharma Formulation
  • Fougera Pharmaceuticals Inc
  • Allergen Plc
  • Johnson & Johnson Services Inc.
  • Bayer AG
  • Merck & Co. Inc.
  • Perrigo New York Inc.
  • Novartis AG
  • Pfizer Inc.
  • Taro Pharmaceutical Industries
  • Sandoz International GmbH
Product Code: SMRC24738

According to Stratistics MRC, the Global Paronychia Treatment Market is accounted for $660.6 million in 2026 and is expected to reach $1335.8 million by 2034 growing at a CAGR of 9.2% during the forecast period. Paronychia is a common nail infection characterized by inflammation of the skin surrounding the fingernail or toenail. This is caused by bacteria, fungi, or both, leading to redness, swelling, and pain. Treatment involves warm soaks, proper wound drainage, topical or oral antibiotics for bacterial infections, antifungal medications for fungal cases, and in severe or recurrent instances, surgical intervention may be necessary.

Market Dynamics:

Driver:

Significant rise in diabetes patients

Diabetic individuals are more susceptible to nail infections like paronychia due to compromised immune systems, nerve damage, and reduced blood circulation, making them susceptible to bacterial or fungal nail infections. With the escalating, global diabetes prevalence, there's been a corresponding increase in the incidence of diabetic-related complications, including nail disorders. Diabetic patients often experience challenges in managing infections, necessitating prompt and effective treatment for paronychia.

Restraint:

Counterfeit medications

Counterfeit or unregulated medications pose a serious threat, potentially offering ineffective, substandard, or even harmful treatments to individuals seeking remedies for paronychia. Such unauthorized drugs lack quality control, proper efficacy, and safety standards, raising concerns among healthcare professionals and patients about treatment reliability and potential adverse effects. The presence of these illegitimate products undermines trust in the market's offerings, hindering the market's growth.

Opportunity:

Advancements in technology

Innovative technologies offer improved drug formulations, targeted delivery systems, and enhanced diagnostic tools. Nanotechnology, transdermal patches, and sophisticated imaging or molecular testing enable more effective and precise treatment approaches. Additionally, telemedicine facilitates remote consultations, expanding access to specialized care. These technological advancements enhance treatment efficacy, patient experience, and the overall landscape of paronychia treatments, fostering opportunities for innovation and growth within the market.

Threat:

Limited awareness

Insufficient knowledge among individuals about paronychia, its symptoms, and the importance of seeking timely medical care may result in delayed diagnosis and treatment. Lack of awareness about preventive measures and available treatment options could hinder early intervention, leading to the progression of nail infections. This limited awareness impacts market growth by reducing the patient pool and impeding the adoption of effective paronychia treatments.

Covid-19 Impact

The deadly corona virus spread quickly around the world, overwhelming hospitals, redirecting resources, and restricting access to non-essential medical services. This caused major disruptions in healthcare systems that impacted paronychia diagnosis, treatment, and management, as well as delayed or decreased access to healthcare services. In order to get their problems resolved those who are experiencing infections and adverse consequences, including pain and inflammation, must wait for the services to resume.

The chronic paronychia segment is expected to be the largest during the forecast period

The chronic paronychia segment is estimated to hold the largest share. Chronic paronychia is a long-term condition that often arises from fungal or bacterial infections, irritants, or predisposing factors such as repetitive trauma or underlying health conditions. Treatments for chronic paronychia include topical antifungal or antibiotic medications, oral therapies, warm soaks, and preventive measures addressing potential irritants. Moreover, chronic paronychia requires long-term, specialised therapy due to its recurrent nature. As a result, there is a dedicated market focus on treating this type of illness.

The gentamicin ointment segment is expected to have the highest CAGR during the forecast period

The gentamicin ointment segment is anticipated to have lucrative growth during the forecast period. Gentamicin ointment contains gentamicin, an antibiotic effective against a wide range of bacteria. Applied directly to the affected nail area, gentamicin ointment targets bacterial infections, reducing inflammation and promoting healing. Furthermore, its localised application and antibacterial properties make it a valuable treatment option for mild-to-moderate bacterial paronychia cases. This segment caters specifically to individuals requiring targeted antimicrobial therapy, contributing to the market's array of topical treatments for addressing bacterial nail infections like paronychia.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to increasing healthcare awareness, a rising prevalence of nail infections, and improving healthcare infrastructure. The region's diverse population and changing lifestyles contribute to the growing incidence of paronychia. Moreover, due to the increased population base suffering from paronychia and their rising spending on the treatment of this issue, and the surging prevalence of favourable government initiatives aimed at improving healthcare infrastructure and promoting awareness about nail infections, this is driving the demand for market growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to a surge in the geriatric population, growing people's knowledge of viable treatments, and the robust presence of major market players in countries like the US and Canada. Moreover, the quick development of cutting-edge paronychia treatment alternatives, such as new topical therapies, antifungal medications, and antibiotics, which have increased the variety of treatment methods offered in clinics and hospitals, is likely to impact the market positively.

Key players in the market

Some of the key players in the Paronychia Treatment Market include Glenmark Generics Ltd, Eli Lilly Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Jonakayem Pharma Formulation, Fougera Pharmaceuticals Inc, Allergen Plc, Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., Perrigo New York Inc., Novartis AG, Pfizer Inc., Taro Pharmaceutical Industries and Sandoz International GmbH.

Key Developments:

In January 2023, The National Medical Products Administration of China announced that they have approved the mobocertinib for treatment of the adult patients with advanced and metastatic non-small lung cancer. The newly developed treatment technique was mostly experienced with mobocertinib including paronychia, diarrhoea, rash, and decreased appetite.

Products Covered:

  • Mupirocin Ointment
  • Gentamicin Ointment
  • Fusidic Acid Ointment
  • Dicloxacillin
  • Other Products

Types Covered:

  • Chronic Paronychia
  • Acute Paronychia
  • Pyogenic Paronychia
  • Candidal Paronychia
  • Other Types

End Users Covered:

  • Dermatology Centers
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Paronychia Treatment Market, By Product

  • 5.1 Introduction
  • 5.2 Mupirocin Ointment
  • 5.3 Gentamicin Ointment
  • 5.4 Fusidic Acid Ointment
  • 5.5 Dicloxacillin
  • 5.6 Other Products

6 Global Paronychia Treatment Market, By Type

  • 6.1 Introduction
  • 6.2 Chronic Paronychia
  • 6.3 Acute Paronychia
  • 6.4 Pyogenic Paronychia
  • 6.5 Candidal Paronychia
  • 6.6 Other Types

7 Global Paronychia Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Dermatology Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Paronychia Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Glenmark Generics Ltd
  • 10.2 Eli Lilly Company
  • 10.3 GlaxoSmithKline plc
  • 10.4 Teva Pharmaceutical Industries Ltd
  • 10.5 Jonakayem Pharma Formulation
  • 10.6 Fougera Pharmaceuticals Inc
  • 10.7 Allergen Plc
  • 10.8 Johnson & Johnson Services Inc.
  • 10.9 Bayer AG
  • 10.10 Merck & Co. Inc.
  • 10.11 Perrigo New York Inc.
  • 10.12 Novartis AG
  • 10.13 Pfizer Inc.
  • 10.14 Taro Pharmaceutical Industries
  • 10.15 Sandoz International GmbH

List of Tables

  • Table 1 Global Paronychia Treatment Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Paronychia Treatment Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Paronychia Treatment Market Outlook, By Mupirocin Ointment (2023-2034) ($MN)
  • Table 4 Global Paronychia Treatment Market Outlook, By Gentamicin Ointment (2023-2034) ($MN)
  • Table 5 Global Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2023-2034) ($MN)
  • Table 6 Global Paronychia Treatment Market Outlook, By Dicloxacillin (2023-2034) ($MN)
  • Table 7 Global Paronychia Treatment Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 8 Global Paronychia Treatment Market Outlook, By Type (2023-2034) ($MN)
  • Table 9 Global Paronychia Treatment Market Outlook, By Chronic Paronychia (2023-2034) ($MN)
  • Table 10 Global Paronychia Treatment Market Outlook, By Acute Paronychia (2023-2034) ($MN)
  • Table 11 Global Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2023-2034) ($MN)
  • Table 12 Global Paronychia Treatment Market Outlook, By Candidal Paronychia (2023-2034) ($MN)
  • Table 13 Global Paronychia Treatment Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 14 Global Paronychia Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 15 Global Paronychia Treatment Market Outlook, By Dermatology Centers (2023-2034) ($MN)
  • Table 16 Global Paronychia Treatment Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 17 Global Paronychia Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 18 North America Paronychia Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 19 North America Paronychia Treatment Market Outlook, By Product (2023-2034) ($MN)
  • Table 20 North America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2023-2034) ($MN)
  • Table 21 North America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2023-2034) ($MN)
  • Table 22 North America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2023-2034) ($MN)
  • Table 23 North America Paronychia Treatment Market Outlook, By Dicloxacillin (2023-2034) ($MN)
  • Table 24 North America Paronychia Treatment Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 25 North America Paronychia Treatment Market Outlook, By Type (2023-2034) ($MN)
  • Table 26 North America Paronychia Treatment Market Outlook, By Chronic Paronychia (2023-2034) ($MN)
  • Table 27 North America Paronychia Treatment Market Outlook, By Acute Paronychia (2023-2034) ($MN)
  • Table 28 North America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2023-2034) ($MN)
  • Table 29 North America Paronychia Treatment Market Outlook, By Candidal Paronychia (2023-2034) ($MN)
  • Table 30 North America Paronychia Treatment Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 31 North America Paronychia Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 32 North America Paronychia Treatment Market Outlook, By Dermatology Centers (2023-2034) ($MN)
  • Table 33 North America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 34 North America Paronychia Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 35 Europe Paronychia Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 36 Europe Paronychia Treatment Market Outlook, By Product (2023-2034) ($MN)
  • Table 37 Europe Paronychia Treatment Market Outlook, By Mupirocin Ointment (2023-2034) ($MN)
  • Table 38 Europe Paronychia Treatment Market Outlook, By Gentamicin Ointment (2023-2034) ($MN)
  • Table 39 Europe Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2023-2034) ($MN)
  • Table 40 Europe Paronychia Treatment Market Outlook, By Dicloxacillin (2023-2034) ($MN)
  • Table 41 Europe Paronychia Treatment Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 42 Europe Paronychia Treatment Market Outlook, By Type (2023-2034) ($MN)
  • Table 43 Europe Paronychia Treatment Market Outlook, By Chronic Paronychia (2023-2034) ($MN)
  • Table 44 Europe Paronychia Treatment Market Outlook, By Acute Paronychia (2023-2034) ($MN)
  • Table 45 Europe Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2023-2034) ($MN)
  • Table 46 Europe Paronychia Treatment Market Outlook, By Candidal Paronychia (2023-2034) ($MN)
  • Table 47 Europe Paronychia Treatment Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 48 Europe Paronychia Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 49 Europe Paronychia Treatment Market Outlook, By Dermatology Centers (2023-2034) ($MN)
  • Table 50 Europe Paronychia Treatment Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 51 Europe Paronychia Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 52 Asia Pacific Paronychia Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 53 Asia Pacific Paronychia Treatment Market Outlook, By Product (2023-2034) ($MN)
  • Table 54 Asia Pacific Paronychia Treatment Market Outlook, By Mupirocin Ointment (2023-2034) ($MN)
  • Table 55 Asia Pacific Paronychia Treatment Market Outlook, By Gentamicin Ointment (2023-2034) ($MN)
  • Table 56 Asia Pacific Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2023-2034) ($MN)
  • Table 57 Asia Pacific Paronychia Treatment Market Outlook, By Dicloxacillin (2023-2034) ($MN)
  • Table 58 Asia Pacific Paronychia Treatment Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 59 Asia Pacific Paronychia Treatment Market Outlook, By Type (2023-2034) ($MN)
  • Table 60 Asia Pacific Paronychia Treatment Market Outlook, By Chronic Paronychia (2023-2034) ($MN)
  • Table 61 Asia Pacific Paronychia Treatment Market Outlook, By Acute Paronychia (2023-2034) ($MN)
  • Table 62 Asia Pacific Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2023-2034) ($MN)
  • Table 63 Asia Pacific Paronychia Treatment Market Outlook, By Candidal Paronychia (2023-2034) ($MN)
  • Table 64 Asia Pacific Paronychia Treatment Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 65 Asia Pacific Paronychia Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 66 Asia Pacific Paronychia Treatment Market Outlook, By Dermatology Centers (2023-2034) ($MN)
  • Table 67 Asia Pacific Paronychia Treatment Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 68 Asia Pacific Paronychia Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 69 South America Paronychia Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 70 South America Paronychia Treatment Market Outlook, By Product (2023-2034) ($MN)
  • Table 71 South America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2023-2034) ($MN)
  • Table 72 South America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2023-2034) ($MN)
  • Table 73 South America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2023-2034) ($MN)
  • Table 74 South America Paronychia Treatment Market Outlook, By Dicloxacillin (2023-2034) ($MN)
  • Table 75 South America Paronychia Treatment Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 76 South America Paronychia Treatment Market Outlook, By Type (2023-2034) ($MN)
  • Table 77 South America Paronychia Treatment Market Outlook, By Chronic Paronychia (2023-2034) ($MN)
  • Table 78 South America Paronychia Treatment Market Outlook, By Acute Paronychia (2023-2034) ($MN)
  • Table 79 South America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2023-2034) ($MN)
  • Table 80 South America Paronychia Treatment Market Outlook, By Candidal Paronychia (2023-2034) ($MN)
  • Table 81 South America Paronychia Treatment Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 82 South America Paronychia Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 83 South America Paronychia Treatment Market Outlook, By Dermatology Centers (2023-2034) ($MN)
  • Table 84 South America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 85 South America Paronychia Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 86 Middle East & Africa Paronychia Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 87 Middle East & Africa Paronychia Treatment Market Outlook, By Product (2023-2034) ($MN)
  • Table 88 Middle East & Africa Paronychia Treatment Market Outlook, By Mupirocin Ointment (2023-2034) ($MN)
  • Table 89 Middle East & Africa Paronychia Treatment Market Outlook, By Gentamicin Ointment (2023-2034) ($MN)
  • Table 90 Middle East & Africa Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2023-2034) ($MN)
  • Table 91 Middle East & Africa Paronychia Treatment Market Outlook, By Dicloxacillin (2023-2034) ($MN)
  • Table 92 Middle East & Africa Paronychia Treatment Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 93 Middle East & Africa Paronychia Treatment Market Outlook, By Type (2023-2034) ($MN)
  • Table 94 Middle East & Africa Paronychia Treatment Market Outlook, By Chronic Paronychia (2023-2034) ($MN)
  • Table 95 Middle East & Africa Paronychia Treatment Market Outlook, By Acute Paronychia (2023-2034) ($MN)
  • Table 96 Middle East & Africa Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2023-2034) ($MN)
  • Table 97 Middle East & Africa Paronychia Treatment Market Outlook, By Candidal Paronychia (2023-2034) ($MN)
  • Table 98 Middle East & Africa Paronychia Treatment Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 99 Middle East & Africa Paronychia Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 100 Middle East & Africa Paronychia Treatment Market Outlook, By Dermatology Centers (2023-2034) ($MN)
  • Table 101 Middle East & Africa Paronychia Treatment Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 102 Middle East & Africa Paronychia Treatment Market Outlook, By Other End Users (2023-2034) ($MN)